-
Je něco špatně v tomto záznamu ?
Which actionable statements qualify as good practice statements In Covid-19 guidelines? A systematic appraisal
O. Dewidar, T. Lotfi, M. Langendam, E. Parmelli, Z. Saz Parkinson, K. Solo, DK. Chu, JL. Mathew, EA. Akl, R. Brignardello-Petersen, RA. Mustafa, L. Moja, A. Iorio, Y. Chi, C. Canelo-Aybar, T. Kredo, J. Karpusheff, AF. Turgeon, P. Alonso-Coello,...
Jazyk angličtina Země Anglie, Velká Británie
Typ dokumentu systematický přehled, časopisecké články
Grantová podpora
001
World Health Organization - International
NLK
ProQuest Central
od 1995-12-01 do Před 6 měsíci
Health & Medicine (ProQuest)
od 2018 do Před 6 měsíci
- MeSH
- COVID-19 * MeSH
- lidé MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- systematický přehled MeSH
- Geografické názvy
- Čína MeSH
OBJECTIVES: To evaluate the development and quality of actionable statements that qualify as good practice statements (GPS) reported in COVID-19 guidelines. DESIGN AND SETTING: Systematic review . We searched MEDLINE, MedSci, China National Knowledge Infrastructure (CNKI), databases of Grading of Recommendations Assessment, Development and Evaluation (GRADE) Guidelines, NICE, WHO and Guidelines International Network (GIN) from March 2020 to September 2021. We included original or adapted recommendations addressing any COVID-19 topic. MAIN OUTCOME MEASURES: We used GRADE Working Group criteria for assessing the appropriateness of issuing a GPS: (1) clear and actionable; (2) rationale necessitating the message for healthcare practice; (3) practicality of systematically searching for evidence; (4) likely net positive consequences from implementing the GPS and (5) clear link to the indirect evidence. We assessed guideline quality using the Appraisal of Guidelines for Research and Evaluation II tool. RESULTS: 253 guidelines from 44 professional societies issued 3726 actionable statements. We classified 2375 (64%) as GPS; of which 27 (1%) were labelled as GPS by guideline developers. 5 (19%) were labelled as GPS by their authors but did not meet GPS criteria. Of the 2375 GPS, 85% were clear and actionable; 59% provided a rationale necessitating the message for healthcare practice, 24% reported the net positive consequences from implementing the GPS. Systematic collection of evidence was deemed impractical for 13% of the GPS, and 39% explained the chain of indirect evidence supporting GPS development. 173/2375 (7.3%) statements explicitly satisfied all five criteria. The guidelines' overall quality was poor regardless of the appropriateness of GPS development and labelling. CONCLUSIONS: Statements that qualify as GPS are common in COVID-19 guidelines but are characterised by unclear designation and development processes, and methodological weaknesses.
American College of Physicians Philadelphia Pennsylvania USA
Amsterdam University Medical Centers University of Amsterdam Amsterdam Netherlands
Clinical Epidemiology Program Ottawa Hospital Research Institute Ottawa Ontario Canada
Clinical Research Institute American University of Beirut Beirut Lebanon
Cochrane Campbell Global Ageing Partnership London UK
Cochrane Canada Hamilton Ontario Canada
Cochrane Germany Cochrane Germany Foundation Freiburg Germany
Cochrane South Africa South African Medical Research Council Cape Town Western Cape South Africa
Deparatment of Family Medicine University of Ottawa Ottawa Ontario Canada
Department of Anesthesiology and Critical Care Medicine Université Laval Québec City Québec Canada
Department of Biomedical Sciences Humanitas University Milan Italy
Department of Health Product Policy and Standards World Health Organization Geneve Switzerland
Department of Internal Medicine American University of Beirut Beirut Lebanon
Department of Medicine McMaster University Hamilton Ontario Canada
Department of Medicine University of Ottawa Faculty of Medicine Ottawa Ontario Canada
Department of Pediatrics Post Graduate Institute of Medical Education and Research Chandigarh India
Iberoamerican Cochrane Center Biomedical Research Institute Sant Pau CIBERESP Barcelona Spain
Instituto de Salud Carlos 3 Agencia de Evaluación de Tecnologías Sanitarias Madrid Spain
Joanna Briggs Institute University of Adelaide Adelaide South Australia Australia
Joint Research Centre European Commission Ispra Italy
Medical Center University of Freiburg Institute for Evidence in Medicine Freiburg Germany
Methods Centre Bruyère Research Institute Ottawa Ontario Canada
National Institute for Health and Care Excellence London UK
School of Epidemiology and Public Health University of Ottawa Ottawa Ontario Canada
Yealth Network Beijing Yealth Technology Co Ltd Beijing China
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc22032521
- 003
- CZ-PrNML
- 005
- 20230131151854.0
- 007
- ta
- 008
- 230120s2022 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1136/bmjebm-2021-111866 $2 doi
- 035 __
- $a (PubMed)35428695
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Dewidar, Omar $u Methods Centre, Bruyère Research Institute, Ottawa, Ontario, Canada $u School of Epidemiology and Public Health, University of Ottawa, Ottawa, Ontario, Canada $1 https://orcid.org/000000016420887X
- 245 10
- $a Which actionable statements qualify as good practice statements In Covid-19 guidelines? A systematic appraisal / $c O. Dewidar, T. Lotfi, M. Langendam, E. Parmelli, Z. Saz Parkinson, K. Solo, DK. Chu, JL. Mathew, EA. Akl, R. Brignardello-Petersen, RA. Mustafa, L. Moja, A. Iorio, Y. Chi, C. Canelo-Aybar, T. Kredo, J. Karpusheff, AF. Turgeon, P. Alonso-Coello, W. Wiercioch, A. Gerritsen, M. Klugar, MX. Rojas, P. Tugwell, VA. Welch, K. Pottie, Z. Munn, R. Nieuwlaat, N. Ford, A. Stevens, J. Khabsa, Z. Nasir, GI. Leontiadis, JJ. Meerpohl, T. Piggott, A. Qaseem, M. Matthews, HJ. Schünemann, eCOVID-19 recommendations map collaborators
- 520 9_
- $a OBJECTIVES: To evaluate the development and quality of actionable statements that qualify as good practice statements (GPS) reported in COVID-19 guidelines. DESIGN AND SETTING: Systematic review . We searched MEDLINE, MedSci, China National Knowledge Infrastructure (CNKI), databases of Grading of Recommendations Assessment, Development and Evaluation (GRADE) Guidelines, NICE, WHO and Guidelines International Network (GIN) from March 2020 to September 2021. We included original or adapted recommendations addressing any COVID-19 topic. MAIN OUTCOME MEASURES: We used GRADE Working Group criteria for assessing the appropriateness of issuing a GPS: (1) clear and actionable; (2) rationale necessitating the message for healthcare practice; (3) practicality of systematically searching for evidence; (4) likely net positive consequences from implementing the GPS and (5) clear link to the indirect evidence. We assessed guideline quality using the Appraisal of Guidelines for Research and Evaluation II tool. RESULTS: 253 guidelines from 44 professional societies issued 3726 actionable statements. We classified 2375 (64%) as GPS; of which 27 (1%) were labelled as GPS by guideline developers. 5 (19%) were labelled as GPS by their authors but did not meet GPS criteria. Of the 2375 GPS, 85% were clear and actionable; 59% provided a rationale necessitating the message for healthcare practice, 24% reported the net positive consequences from implementing the GPS. Systematic collection of evidence was deemed impractical for 13% of the GPS, and 39% explained the chain of indirect evidence supporting GPS development. 173/2375 (7.3%) statements explicitly satisfied all five criteria. The guidelines' overall quality was poor regardless of the appropriateness of GPS development and labelling. CONCLUSIONS: Statements that qualify as GPS are common in COVID-19 guidelines but are characterised by unclear designation and development processes, and methodological weaknesses.
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a COVID-19 $7 D000086382
- 651 _2
- $a Čína $7 D002681
- 655 _2
- $a systematický přehled $7 D000078182
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Lotfi, Tamara $u Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, Ontario, Canada $u Michael G DeGroote Cochrane Canada and McMaster GRADE Centres, McMaster University, Hamilton, Ontario, Canada $u WHO Collaborating Center for Infectious Diseases, Research Methods and Recommendations, McMaster University, Hamilton, Ontario, Canada
- 700 1_
- $a Langendam, Miranda $u Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, Netherlands
- 700 1_
- $a Parmelli, Elena $u Joint Research Centre, European Commission, Ispra, Italy
- 700 1_
- $a Saz Parkinson, Zuleika $u Instituto de Salud Carlos III, Agencia de Evaluación de Tecnologías Sanitarias, Madrid, Spain
- 700 1_
- $a Solo, Karla $u Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, Ontario, Canada $u Michael G DeGroote Cochrane Canada and McMaster GRADE Centres, McMaster University, Hamilton, Ontario, Canada $u WHO Collaborating Center for Infectious Diseases, Research Methods and Recommendations, McMaster University, Hamilton, Ontario, Canada $1 https://orcid.org/0000000161349140
- 700 1_
- $a Chu, Derek K $u Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, Ontario, Canada $u Department of Medicine, McMaster University, Hamilton, Ontario, Canada $1 https://orcid.org/0000000182694496
- 700 1_
- $a Mathew, Joseph L $u Department of Pediatrics, Post Graduate Institute of Medical Education and Research, Chandigarh, India
- 700 1_
- $a Akl, Elie A $u Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, Ontario, Canada $u Department of Internal Medicine, American University of Beirut, Beirut, Lebanon
- 700 1_
- $a Brignardello-Petersen, Romina $u Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, Ontario, Canada $u Michael G DeGroote Cochrane Canada and McMaster GRADE Centres, McMaster University, Hamilton, Ontario, Canada
- 700 1_
- $a Mustafa, Reem A $u Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, Ontario, Canada $u Internal Medicine, Division of Nephrology and Hypertension, University of Kansas School of Medicine, Kansas City, Kansas, USA
- 700 1_
- $a Moja, Lorenzo $u Department of Health Product Policy and Standards, World Health Organization, Geneve, Switzerland
- 700 1_
- $a Iorio, Alfonso $u Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, Ontario, Canada $u Michael G DeGroote Cochrane Canada and McMaster GRADE Centres, McMaster University, Hamilton, Ontario, Canada $u Department of Medicine, McMaster University, Hamilton, Ontario, Canada
- 700 1_
- $a Chi, Yuan $u Yealth Network, Beijing Yealth Technology Co., Ltd, Beijing, China $u Cochrane Campbell Global Ageing Partnership, London, UK
- 700 1_
- $a Canelo-Aybar, Carlos $u Iberoamerican Cochrane Center, Biomedical Research Institute Sant Pau-CIBERESP, Barcelona, Spain
- 700 1_
- $a Kredo, Tamara $u Cochrane South Africa, South African Medical Research Council, Cape Town, Western Cape, South Africa $u Clinical Pharmacology, Department of Medicine, Stellenbosch University, Stellenbosch, Western Cape, South Africa $1 https://orcid.org/0000000171159535
- 700 1_
- $a Karpusheff, Justine $u National Institute for Health and Care Excellence, London, UK
- 700 1_
- $a Turgeon, Alexis F $u Centre de Recherche du Centre Hospitalier Affilié Universitaire de Québec (CHA), CHA-Hôpital de l'Enfant-Jésus, Université Laval, Quebec, Quebec, Canada $u Department of Anesthesiology and Critical Care Medicine, Université Laval, Québec City, Québec, Canada
- 700 1_
- $a Alonso-Coello, Pablo $u Iberoamerican Cochrane Center, Biomedical Research Institute Sant Pau-CIBERESP, Barcelona, Spain
- 700 1_
- $a Wiercioch, Wojtek $u Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, Ontario, Canada $u Michael G DeGroote Cochrane Canada and McMaster GRADE Centres, McMaster University, Hamilton, Ontario, Canada $u WHO Collaborating Center for Infectious Diseases, Research Methods and Recommendations, McMaster University, Hamilton, Ontario, Canada
- 700 1_
- $a Gerritsen, Annette $u Cochrane South Africa, South African Medical Research Council, Cape Town, Western Cape, South Africa
- 700 1_
- $a Klugar, Miloslav $u Czech National Centre for Evidence-Based Healthcare and Knowledge Translation, Institute of Biostatistics and Analyses, Masaryk University, Brno, Czech Republic $1 https://orcid.org/0000000228047295
- 700 1_
- $a Rojas, María Ximena $u Department of Clinical Epidemiology and Public Health, Institut d'Investigació Biomèdica Sant Pau IIB Sant Pau, Barcelona, Spain
- 700 1_
- $a Tugwell, Peter $u Department of Medicine, University of Ottawa Faculty of Medicine, Ottawa, Ontario, Canada $u Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada
- 700 1_
- $a Welch, Vivian Andrea $u Methods Centre, Bruyère Research Institute, Ottawa, Ontario, Canada $u School of Epidemiology and Public Health, University of Ottawa, Ottawa, Ontario, Canada $1 https://orcid.org/0000000252387097
- 700 1_
- $a Pottie, Kevin $u Deparatment of Family Medicine, University of Ottawa, Ottawa, Ontario, Canada
- 700 1_
- $a Munn, Zachary $u Joanna Briggs Institute, University of Adelaide, Adelaide, South Australia, Australia
- 700 1_
- $a Nieuwlaat, Robby $u Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, Ontario, Canada
- 700 1_
- $a Ford, Nathan $u Department of HIV, Hepatitis and Sexually Transmitted Infections, World Health Organization, Geneva, Switzerland
- 700 1_
- $a Stevens, Adrienne $u Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, Ontario, Canada $u Michael G DeGroote Cochrane Canada and McMaster GRADE Centres, McMaster University, Hamilton, Ontario, Canada
- 700 1_
- $a Khabsa, Joanne $u Clinical Research Institute, American University of Beirut, Beirut, Lebanon $1 https://orcid.org/0000000243363501
- 700 1_
- $a Nasir, Zil $u Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, Ontario, Canada $u Michael G DeGroote Cochrane Canada and McMaster GRADE Centres, McMaster University, Hamilton, Ontario, Canada
- 700 1_
- $a Leontiadis, Grigorios I $u Michael G DeGroote Cochrane Canada and McMaster GRADE Centres, McMaster University, Hamilton, Ontario, Canada $u Department of Medicine, McMaster University, Hamilton, Ontario, Canada
- 700 1_
- $a Meerpohl, Joerg J $u Cochrane Germany, Cochrane Germany Foundation, Freiburg, Germany $u Medical Center - University of Freiburg, Institute for Evidence in Medicine, Freiburg, Germany
- 700 1_
- $a Piggott, Thomas $u Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, Ontario, Canada $u Michael G DeGroote Cochrane Canada and McMaster GRADE Centres, McMaster University, Hamilton, Ontario, Canada $u WHO Collaborating Center for Infectious Diseases, Research Methods and Recommendations, McMaster University, Hamilton, Ontario, Canada $1 https://orcid.org/0000000316435386
- 700 1_
- $a Qaseem, Amir $u American College of Physicians, Philadelphia, Pennsylvania, USA
- 700 1_
- $a Matthews, Micayla $u Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, Ontario, Canada $u Michael G DeGroote Cochrane Canada and McMaster GRADE Centres, McMaster University, Hamilton, Ontario, Canada $u WHO Collaborating Center for Infectious Diseases, Research Methods and Recommendations, McMaster University, Hamilton, Ontario, Canada
- 700 1_
- $a Schünemann, Holger J $u Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, Ontario, Canada schuneh@mcmaster.ca $u Michael G DeGroote Cochrane Canada and McMaster GRADE Centres, McMaster University, Hamilton, Ontario, Canada $u WHO Collaborating Center for Infectious Diseases, Research Methods and Recommendations, McMaster University, Hamilton, Ontario, Canada $u Department of Medicine, McMaster University, Hamilton, Ontario, Canada $u Department of Biomedical Sciences, Humanitas University, Milan, Italy $u Cochrane Canada, Hamilton, Ontario, Canada $1 https://orcid.org/0000000332118479
- 710 2_
- $a eCOVID-19 recommendations map collaborators
- 773 0_
- $w MED00210182 $t BMJ evidence-based medicine $x 2515-4478 (online) $g Roč. 27, č. 6 (2022), s. 361-369
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/35428695 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20230120 $b ABA008
- 991 __
- $a 20230131151849 $b ABA008
- 999 __
- $a ok $b bmc $g 1891343 $s 1183856
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2022 $b 27 $c 6 $d 361-369 $e 20220415 $i 2515-4478 (online) $m BMJ evidence-based medicine $n BMJ Evid Based Med $x MED00210182
- GRA __
- $a 001 $p World Health Organization $2 International
- LZP __
- $a Pubmed-20230120
